Yurchenko M. CD150 expression and CD150-mediated signaling pathways in normal and malignant B lymphocytes

Українська версія

Thesis for the degree of Candidate of Sciences (CSc)

State registration number

0406U000687

Thesis Registration Form

0406U000687.pdf

Applicant for

Specialization

  • 14.01.07 - Онкологія

22-02-2006

Specialized Academic Board

Д 26.155.01

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine

Essay

The dissertation covers the studies of CD150 expression and CD150-mediated signaling pathways in lymphoma cells originated from B lymphocytes. CD150 is co-expressed with SH2D1A adaptor protein in lymphoma cells with activated B cell phenotype, such as Hodgkin's lymphoma and ABC-type diffuse large B cell lymphoma (ABC-DLBCL). It was found that malignant cells in classical Hodgkin's lymphoma express membrane and soluble splice isoforms of CD150 receptor on mRNA level. In malignant B cells, Akt and MAPK (ERK1/2, JNK2, p38MAPK) signaling pathways are regulated via CD150 receptor. SH2D1A adaptor protein, Syk, Lyn and Btk tyrosine kinases are involved in regulation of CD150-mediated signaling.

Read more

Files

Dissertation.doc

Dissertation.doc

aref.doc

Similar theses

0524U000115

Pavlo G. Yakovlev

Rationale for the choice of complex organ-preserving treatment of patients with high-grade bladder cancer

0523U100184

Vyacheslav Maksymovskyi

Optimization of combined treatment of patients with peritoneal carcinomatosis and other intra-abdominal metastases of different primary origin

0523U100072

Vitruk Yuriy

Optimization of Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Renal Cell Carcinoma

0423U100001

Samokhvalova Olena O.

Clinical features and molecular biochemical factors for the prognosis of vulvar cancer recurrence

0521U101888

Stakhovskyi Oleksandr E.

Combined treatment optimization in muscle-invasive bladder cancer